世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場2022-2030:種類別(血清、肝線維症、アポトーシス、酸化ストレス)、最終用途別(製薬&CRO産業、病院)、地域別

【英語タイトル】Non-alcoholic Steatohepatitis Biomarkers Market Size, Share & Trends Analysis Report By Type (Serum, Hepatic Fibrosis, Apoptosis, Oxidative Stress), By End-use (Pharma & CRO Industry, Hospitals), By Region, And Segment Forecasts, 2022 - 2030

Grand View Researchが出版した調査資料(GRV22NV061)・商品コード:GRV22NV061
・発行会社(調査会社):Grand View Research
・発行日:2022年10月10日
・ページ数:120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:バイオ
◆販売価格オプション(消費税別)
Single UserUSD5,950 ⇒換算¥880,600見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算¥1,028,600見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算¥1,324,600見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Grand View Research社は、世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模が、2022年から2030年の間に年平均23.6%成長し、2030年までに54億ドルに達すると予測しています。当調査レポートでは、非アルコール性脂肪肝炎(NASH)バイオマーカーの世界市場について総合的に調査・分析を行い、調査手法・範囲、エグゼクティブサマリー、産業見通し、競争状況、種類別(血清、肝線維症、アポトーシス、酸化ストレス、その他)、最終用途別(製薬&CRO産業、病院、診断研究所、学術研究機関)、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、企業情報などの構成でまとめています。なお、当書に掲載されている企業情報には、GENFIT、Prometheus Laboratories、AstraZeneca、Siemens Medical Solutions USA, Inc.、Bristol-Myers Squibb Company、BioPredictive、Quest Diagnostics、Exalenz Bioscience Ltd、Pfizer, Inc.、Laboratory Corporation of America Holdingsなどが含まれています。
・調査手法・範囲
・エグゼクティブサマリー
・産業見通し
・競争状況
・世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模:種類別
- 血清バイオマーカーの市場規模
- 肝線維症バイオマーカーの市場規模
- アポトーシスバイオマーカーの市場規模
- 酸化ストレスバイオマーカーの市場規模
- その他バイオマーカーの市場規模
・世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模:最終用途別
- 製薬&CRO産業における市場規模
- 病院における市場規模
- 診断研究所における市場規模
- 学術研究機関における市場規模
・世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模:地域別
- 北米の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模
- ヨーロッパの非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模
- アジア太平洋の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模
- 中南米の非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模
- 中東・アフリカの非アルコール性脂肪肝炎(NASH)バイオマーカー市場規模
・企業情報

Non-alcoholic Steatohepatitis Biomarkers Market Growth & Trends

The global non-alcoholic steatohepatitis biomarkers market size is expected to reach USD 5.4 billion by 2030, registering a CAGR of 23.6% during the forecast period, according to a new report by Grand View Research, Inc. The growth of the Non-alcoholic Steatohepatitis (NASH) biomarkers market is attributed to rising prevalence of chronic diseases and rising demand for providing novel diagnostic tools. Nonalcoholic Fatty Liver Disease (NAFLD) is more prevalent in people with specific diseases, such as obesity, and diseases that may be linked to obesity, including type 2 diabetes. One-third to two-thirds of people with type 2 diabetes are projected to have NAFLD.

According to April 2021 study by NIH, up to 75% of overweight individuals and more than 90% of individuals with extreme obesity have NAFLD. An increasing obese population and unhealthy food habits are creating a favorable environment for the development of liver disease. Therefore, the rising prevalence of chronic liver disease is expected to fuel the demand for NASH biomarkers. The ongoing research activities in this sector are likely to sustain the market growth.

The primary factor pertaining to growth is the increasing incidence of chronic liver illnesses like nonalcoholic steatohepatitis and the need to develop ways for their early detection and diagnosis. The market for non-alcoholic steatohepatitis biomarkers has enormous growth potential despite the lack of a single reliable non-invasive procedure to diagnose NAFLD. Another growth factor is the increasing demand for non-invasive diagnosis methods as other diagnostic procedures available are intrusive and expensive, thus they are not suitable for patients.

Moreover, major key players operating in the market are focusing on collaborations aiming toward expanding awareness among the population is further propelling the growth of market. For instance, in June 2022, Echosens and Novo Nordisk announced a partnership to increase awareness about NASH and accelerate the adoption rate of noninvasive screening methods such as Echosens’ FibroScan system. The partnership strives to double the diagnosis rate of severe and advanced NASH by 2025.

The high cost of diagnosing NASH is a significant factor hindering the growth of the market. For instance, liver biopsy for NASH for monitoring and diagnosis of the disease can cost up to USD 3500 making it an invasive and expensive procedure. Furthermore, regulatory authorities such as the FDA have strict rules for biomarker approval, which is slowing industry expansion.

Non-alcoholic Steatohepatitis Biomarkers Market Report Highlights

• By type, the serum biomarkers segment held a larger share of the NASH biomarkers market since serum biomarkers are most effective and most widely used diagnosis tool

• By end-use, the pharma & CRO industry segment is expected to show the fastest growth over the forecast period due to the high demand for non-invasive tools for the diagnosis of liver diseases

• North America dominated the global market in 2021, owing to the rising prevalence of infectious diseases, cardiovascular diseases, and cancer

• Key players operating in the market are focusing on collaborations and partnerships focusing on expanding the awareness about early diagnosis and presence of diagnostic tools for determining NAFLD and NASH

❖ レポートの目次 ❖

Table of Contents

Chapter 1 NASH Biomarkers Market: Methodology and Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates and forecast timeline
1.3 Information Procurement
1.3.1 Purchased database
1.3.2 GVR’s internal database
1.3.3 Secondary sources
1.3.4 Primary research
1.3.5 Details of primary research
1.4 Information or Data Analysis
1.4.1 Data analysis models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity flow analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.2 Volume price analysis (model 2)
1.6.2.1 Approach 2: Volume price analysis
1.6.2.2 Revenue modeling
1.7 List of Secondary Sources
1.8 List of Primary Sources
Chapter 2 NASH Biomarkers Market: Executive Summary
2.1 Market Summary
Chapter 3 NASH Biomarkers Market: Industry Outlook
3.1 Market Lineage Outlook
3.1.1 Parent Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Driver Analysis
3.3.1.1 Rising prevalence of chronic liver diseases
3.3.1.2 Increasing demand for non-invasive diagnostics for NASH biomarkers
3.3.1.3 Rising investment by government and private organizations in R&D for NASH biomarkers therapeutics
3.3.2 Market Restraint Analysis
3.3.2.1 Side-effects and risks associated with NASH therapeutics
3.4 Porter’s Five Forces Analysis
3.5 SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.6 Regulatory Framework
3.7 Pipeline Analysis
Chapter 4 NASH Biomarkers Market: Competitive Landscape
4.1 Recent developments & impact analysis, by key market participants
4.1.1 Ansoff Matrix
4.2 Major deals & strategic alliances analysis
4.2.1 Joint Ventures
4.2.2 Licensing and Partnerships
4.2.3 Technological Collaborations
4.3 Company/Competition Categorization
4.4 Vendor Landscape
4.4.1 List Of Key Distributors and Channel Partners
4.4.2 Key Customers
4.5 Public Companies
4.5.1 Company Market Position Analysis
4.6 Private Companies
4.6.1 List Of Key Emerging Companies
4.6.2 Regional Network Map
Chapter 5 NASH Biomarkers Market: Type Business Analysis
5.1 Definition and Scope
5.2 Type Market Share Analysis, 2021 & 2030
5.3 Global NASH Biomarkers Market, By Type, 2018 To 2030
5.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
5.4.1 Serum Biomarkers
5.4.1.1 Serum Biomarkers Market 2018 – 2030 (USD Million)
5.4.2 Hepatic Fibrosis Biomarkers
5.4.2.1 Hepatic Fibrosis Biomarkers Market, 2018 – 2030 (USD Million)
5.4.3 Apoptosis Biomarkers
5.4.3.1 Apoptosis Biomarkers Market, 2018 – 2030 (USD Million)
5.4.4 Oxidative Stress Biomarkers
5.4.4.1 Oxidative Stress Biomarkers Market, 2018 – 2030 (USD Million)
5.4.5 Others
5.4.5.1 Others Market, 2018 – 2030 (USD Million)
Chapter 6 NASH Biomarkers Market: End-Use Business Analysis
6.1 Definition and Scope
6.2 End-Use Market Share Analysis, 2021 & 2030
6.3 Global NASH Biomarkers Market, By End-Use, 2018 To 2030
6.4 Market Size & Forecasts and Trend Analyses, 2018 to 2030
6.4.1 Pharma & CRO Industry
6.4.1.1 Pharma & CRO Industry Market 2018 – 2030 (USD Million)
6.4.2 Hospitals
6.4.2.1 Hospitals Market, 2018 – 2030 (USD Million)
6.4.3 Diagnostic Labs
6.4.3.1 Diagnostic Labs Market, 2018 – 2030 (USD Million)
6.4.4 Academic Research Institutes
6.4.4.1 Academic Research Institutes Market, 2018 – 2030 (USD Million)
Chapter 7 NASH Biomarkers Market: Regional Business Analysis
7.1 Definition & Scope
7.2 Regional Market Share Analysis, 2021 & 2030
7.3 Regional Market Dashboard
7.4 Regional Market Snapshot
7.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
7.5.1 North America
7.5.2 Europe
7.5.3 Asia Pacific
7.5.4 Latin America
7.5.5 MEA
7.6 Market Size, & Forecasts, Trend Analysis, 2021 to 2030
7.7 North America
7.7.1 North America NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.7.2 U.S.
7.7.2.1 U.S. NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.7.3 Canada
7.7.3.1 Canada NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8 Europe
7.8.1 Europe NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.2 U.K.
7.8.2.1 U.K. NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.3 Germany
7.8.3.1 Germany NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.4 France
7.8.4.1 France NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.5 Italy
7.8.5.1 Italy NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.8.6 Spain
7.8.6.1 Spain NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9 Asia Pacific
7.9.1 Asia Pacific NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.2 Japan
7.9.2.1 Japan NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.3 China
7.9.3.1 China NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.4 India
7.9.4.1 India NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.5 Australia
7.9.5.1 Australia NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.9.6 South Korea
7.9.6.1 South Korea NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10 Latin America
7.10.1 Latin America NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10.2 Brazil
7.10.2.1 Brazil NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10.3 Mexico
7.10.3.1 Mexico NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.10.4 Argentina
7.10.4.1 Argentina NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11 MEA
7.11.1 MEA NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11.2 South Africa
7.11.2.1 South Africa NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11.3 Saudi Arabia
7.11.3.1 Saudi Arabia NASH Biomarkers Market, 2018 – 2030 (USD Million)
7.11.4 UAE
7.11.4.1 UAE NASH Biomarkers Market, 2018 – 2030 (USD Million)
Chapter 8 NASH Biomarkers Market: Company Profiling
8.1 Company Profiles
8.1.1. GENFIT
8.1.1.1 Company overview
8.1.1.2 Financial performance
8.1.1.3 Product benchmarking
8.1.1.4 Strategic initiatives
8.1.2. Prometheus Laboratories
8.1.2.1 Company overview
8.1.2.2 Financial performance
8.1.2.3 Product benchmarking
8.1.2.4 Strategic initiatives
8.1.3. AstraZeneca
8.1.3.1 Company overview
8.1.3.2 Financial performance
8.1.3.3 Product benchmarking
8.1.3.4 Strategic initiatives
8.1.4. Siemens Medical Solutions USA, Inc.
8.1.4.1 Company overview
8.1.4.2 Financial performance
8.1.4.3 Product benchmarking
8.1.4.4 Strategic initiatives
8.1.5. Bristol-Myers Squibb Company
8.1.5.1 Company overview
8.1.5.2 Financial performance
8.1.5.3 Product benchmarking
8.1.5.4 Strategic initiatives
8.1.6. BioPredictive
8.1.6.1 Company overview
8.1.6.2 Financial performance
8.1.6.3 Product benchmarking
8.1.6.4 Strategic initiatives
8.1.7. Quest Diagnostics
8.1.7.1 Company overview
8.1.7.2 Financial performance
8.1.7.3 Product benchmarking
8.1.7.4 Strategic initiatives
8.1.8 Exalenz Bioscience Ltd
8.1.8.1 Company overview
8.1.8.2 Financial performance
8.1.8.3 Product benchmarking
8.1.8.4 Strategic initiatives
8.1.9 Pfizer, Inc.
8.1.9.1 Company overview
8.1.9.2 Financial performance
8.1.9.3 Product benchmarking
8.1.9.4 Strategic initiatives
8.1.10 Laboratory Corporation of America Holdings
8.1.10.1 Company overview
8.1.10.2 Financial performance
8.1.10.3 Product benchmarking
8.1.10.4 Strategic initiatives



★調査レポート[世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場2022-2030:種類別(血清、肝線維症、アポトーシス、酸化ストレス)、最終用途別(製薬&CRO産業、病院)、地域別] (コード:GRV22NV061)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の非アルコール性脂肪肝炎(NASH)バイオマーカー市場2022-2030:種類別(血清、肝線維症、アポトーシス、酸化ストレス)、最終用途別(製薬&CRO産業、病院)、地域別]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆